Angelalign Technology Inc., a prominent player in the health care sector, has recently made significant strides in its business operations and strategic partnerships. Based in China, the company specializes in the production and distribution of medical devices, with a particular focus on invisible orthodontic aligners. Angelalign Technology Limited is publicly traded on the Hong Kong Stock Exchange, and its financial performance has been noteworthy in recent times.
As of 10 February 2026, Angelalign’s share price closed at HKD 76.95, nearing its 52-week high of HKD 78.85, also recorded on the same day. This performance marks a significant recovery from its 52-week low of HKD 45.75, which was observed on 16 April 2025. The substantial intra-year range of approximately HKD 33.10 underscores the volatility and dynamic nature of the company’s stock performance over the past year.
The company’s market capitalization stands at 12,470,000,000 HKD, reflecting its substantial presence in the health care sector. Financially, Angelalign’s valuation multiples indicate a price-to-earnings ratio of 57.85 and a price-to-book ratio of 3.36712. These figures suggest that the market is placing a premium on the company’s earnings and book value, highlighting investor confidence in its growth prospects and operational capabilities.
In a significant corporate development, Angelalign Technology Limited announced on 4 November 2025, its expansion of strategic partnerships with Dexis™, Shining 3D, and Panda Scanner. This move is concurrent with the launch of iOrtho Release 5.3, a new iteration of its orthodontic aligner technology. These partnerships are expected to enhance the company’s technological capabilities and market reach, further solidifying its position in the competitive health care landscape.
As of the latest updates, no subsequent corporate disclosures have been made following the November announcement. However, the strategic initiatives undertaken by Angelalign Technology Inc. are anticipated to drive future growth and innovation within the company, reinforcing its commitment to advancing medical device technology and expanding its market presence both domestically and internationally.
